Hyperion DeFi (NASDAQ:HYPD) Director Acquires $90,300.00 in Stock

Hyperion DeFi, Inc. (NASDAQ:HYPD) Director Michael Geltzeiler bought 30,000 shares of the firm’s stock in a transaction on Wednesday, December 17th. The stock was purchased at an average price of $3.01 per share, with a total value of $90,300.00. Following the transaction, the director owned 88,015 shares in the company, valued at $264,925.15. The trade was a 51.71% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Hyperion DeFi Stock Performance

Shares of HYPD traded up $0.24 during mid-day trading on Friday, reaching $3.24. 61,636 shares of the company’s stock traded hands, compared to its average volume of 1,555,262. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.25 and a current ratio of 2.25. The business’s 50-day moving average price is $5.40 and its 200-day moving average price is $7.50. The stock has a market capitalization of $26.48 million, a P/E ratio of -0.80 and a beta of 2.80. Hyperion DeFi, Inc. has a 12 month low of $0.85 and a 12 month high of $17.99.

Hyperion DeFi (NASDAQ:HYPD) last posted its earnings results on Friday, November 14th. The company reported $0.05 EPS for the quarter. Hyperion DeFi had a negative return on equity of 119.59% and a negative net margin of 62,238.41%.The firm had revenue of $0.36 million for the quarter. Equities analysts predict that Hyperion DeFi, Inc. will post -41.6 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts recently weighed in on HYPD shares. Weiss Ratings restated a “sell (d-)” rating on shares of Hyperion DeFi in a report on Wednesday, October 8th. Wall Street Zen raised Hyperion DeFi from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd. Finally, Cantor Fitzgerald initiated coverage on Hyperion DeFi in a research report on Tuesday. They set an “overweight” rating and a $4.00 target price on the stock. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $3.00.

Hyperion DeFi Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.